FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer By Ogkologos - October 28, 2024 633 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Addition of an EGFR Antibody to Fluorouracil/Folinic Acid Maintenance Therapy in... September 22, 2021 Complete Cancer Prevalence in Europe in 2020 Reveals an Increased Proportion... February 1, 2024 New breast and lung cancer treatments approved in Scotland January 19, 2022 ESMO Welcomes New Cancer Focused UN Political Declaration on Non-Communicable Diseases October 6, 2025 Load more HOT NEWS 31-Year-Old Woman Diagnosed with Breast Cancer Just 11 Days Before Her... Outcomes of Cancer Patients with SARS-CoV-2 Infection in Veneto Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t... New Safety Signal for Use of Ibrutinib in Combination with Rituximab...
